S&P 500 Futures
(-0.08%) 5 304.25 points
Dow J Futures
(-0.09%) 40 140 points
Nasdaq Futures
(-0.05%) 18 465 points
Oil
(-0.07%) $83.11
Gas
(-0.62%) $1.752
Gold
(0.73%) $2 254.80
Silver
(0.74%) $25.10
Platinum
(0.21%) $923.00
USD/EUR
(0.08%) $0.927
USD/NOK
(0.29%) $10.87
USD/GBP
(0.03%) $0.792
USD/RUB
(-0.15%) $92.44

Realtime updates for Immatics N.V. [IMTX]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
BUY
66.67%
return 2.54%
SELL
33.33%
return 5.15%
Last Updated28 Mar 2024 @ 16:00

-5.32% $ 10.51

SELL 64193 min ago

@ $11.29

Issued: 13 Feb 2024 @ 15:33


Return: -6.91%


Previous signal: Feb 13 - 09:30


Previous signal: Buy


Return: 2.98 %

Live Chart Being Loaded With Signals

Commentary (28 Mar 2024 @ 16:00):

Warning: Trying to access array offset on null in /home/getagraph/public_html/stock.php on line 302
Profile picture for Immatics N.V.

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States...

Stats
Today's Volume 1.03M
Average Volume 522 655
Market Cap 1.08B
EPS $0 ( 2024-03-19 )
Next earnings date ( $-0.740 ) 2024-05-21
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -8.08
ATR14 $0.0170 (0.16%)

Volume Correlation

Long: -0.41 (neutral)
Short: -0.47 (neutral)
Signal:(38.203) Neutral

Immatics N.V. Correlation

10 Most Positive Correlations
RMRM0.966
RXT0.929
SWAV0.925
UCBI0.922
NFE0.918
CCRN0.917
NVTSW0.916
GBCI0.915
FIBK0.914
THTX0.914
10 Most Negative Correlations
MLCO-0.927
EZGO-0.926
RXDX-0.925
FWONK-0.922
BRAC-0.92
LUNA-0.918
HWCC-0.917
BKNG-0.917
MLVF-0.916
MOMO-0.915

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Immatics N.V. Correlation - Currency/Commodity

The country flag 0.61
( weak )
The country flag 0.12
( neutral )
The country flag 0.00
( neutral )
The country flag 0.62
( weak )
The country flag -0.25
( neutral )
The country flag -0.02
( neutral )

Immatics N.V. Financials

Annual 2023
Revenue: $54.00M
Gross Profit: $54.00M (100.00 %)
EPS: $-1.200
Q4 2023
Revenue: $15.92M
Gross Profit: $15.92M (100.00 %)
EPS: $-0.310
Q3 2023
Revenue: $5.93M
Gross Profit: $5.93M (100.00 %)
EPS: $-0.320
Q2 2023
Revenue: $22.35M
Gross Profit: $-4.96M (-22.20 %)
EPS: $-0.320

Financial Reports:

No articles found.

Immatics N.V.

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

About Live Signals

The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.

The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators